A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea

Status Completed

Clinical Trial Summary

The main aim of the study is to check the side effects from overnight treatment with danavorexton and assess the tolerability of varying doses of danavorexton administered intravenously. Before starting treatment with danavorexton, participants will keep a sleep diary and use an under-mattress sensor for at least 7 nights to check regular sleep habits. There will be 3 Treatment Period up to 14 days apart. In each Treatment Period, participants will receive an intravenous (through the vein) infusion of either danavorexton or a placebo starting in the evening and continuing over a 10-hour period. A placebo looks exactly like danavorexton but does not have any medicine in it. Participants will take part in a follow-up phone appointment about a week after the last Treatment Period.

Clinical Trial Description

The drug being tested in this study is called danavorexton. The study will look at the safety, tolerability, pharmacokinetic (PK), and pharmacodynamics (PD) effects of danavorexton. The study will enroll approximately 18 participants (to acquire data in 'n' greater than or equal to [>=] 12). Each participant will receive one of the following treatments in each Treatment Period: Danavorexton low dose (LD), danavorexton high dose (HD), or placebo. All participants will receive all 3 treatments. A washout period of a minimum of 2 days up to 14 days will be maintained between the end of infusion to the start time of next infusion. The order in which each participant receives the 3 treatments will be randomly assigned. Treatment order will remain undisclosed to the participants and study doctor during the study (unless there is an urgent medical need). This single-center trial will be conducted in Australia. The overall time to participate in this study is up to 69 days. Participants will be followed remotely until 5 to 9 days after the last dose of study drug in the Treatment Period 3. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05180890
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 1
Start date	March 10, 2022
Completion date	November 23, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05582070` - Effect on Sleep of Surgical Treatment of Severe Nasal Obstruction	N/A
Recruiting	`NCT03919955` - A Novel Pharmacological Therapy for Obstructive Sleep Apnea	Phase 2
Completed	`NCT03927547` - Sleep Disordered Breathing and Cardiopulmonary Disease in Peruvian Highlanders	N/A
Recruiting	`NCT04007380` - Psychosocial, Cognitive, and Behavioral Consequences of Sleep-disordered Breathing After SCI	N/A
Completed	`NCT02188498` - Electrocardiography Data Analysis in Sleep Disorders
Completed	`NCT01503164` - Effects of Continuous Positive Airway Pressure (CPAP) on Glucose Metabolism	N/A
Recruiting	`NCT00747890` - Surgical Treatment of Mild Obstructive Sleep Apnea	N/A
Active, not recruiting	`NCT00738179` - Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea to Prevent Cardiovascular Disease	Phase 3
Completed	`NCT00841906` - Alice PDx User/Validation Extended Trial	N/A
Completed	`NCT00202501` - Usefulness of Nasal Continuous Positive Airway Pressure (CPAP) Treatment in Patients With a First Ever Stroke and Sleep Apnea Syndrome	N/A
Completed	`NCT00047463` - Effects of Treating Obstructive Sleep Apnea in Epilepsy	Phase 2
Not yet recruiting	`NCT06029881` - Portable System for Non-intrusive Monitoring of Sleep
Recruiting	`NCT06093347` - Central Apnoea Monitor Study
Terminated	`NCT05445869` - Severe OSA Study (SOS)	N/A
Withdrawn	`NCT04096261` - The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease
Recruiting	`NCT04575740` - Phenotyping Mechanistic Pathways for Adverse Health Outcomes in Sleep Apnea	N/A
Completed	`NCT04676191` - Validation of a Contactless Vital Signs Measurement Sensor	N/A
Recruiting	`NCT06015620` - Comorbidities Resolution After MGB Surgery and Change in Body Composition
Completed	`NCT06051097` - Metabolic Syndrome and Obstructive Sleep Apnea
Completed	`NCT05687097` - Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.